Drug Development/R&D
New medicines lead to improved patient outcomes and societal benefits, but R&D is a long and costly process. Ongoing health economics research aims to find the right balance between incentivising manufacturers to innovate and ensuring affordable access for health systems.
Incentives for R&D for New Antimicrobial Drugs
1 April 2011
Antimicrobial resistance (AMR) is becoming a major global public health threat and has begun to command attention from European and US policy makers. An initial focus…
Priority Review Vouchers to Encourage Innovation for Neglected Diseases
1 January 2011
Priority Review Vouchers (PRVs) are awarded in the US to companies that gain approval there for a new drug for one of sixteen tropical diseases, under…
New Drugs to Tackle Antimicrobial Resistance: EU Policy Options
1 October 2010
Antimicrobial resistance (AMR) to drugs, a natural and unavoidable consequence of treating infectious diseases, is a growing global public health threat. The EU Commission is to…
Innovation in Medicines: Can We Value Progress?
1 August 2010
Summarised in this publication are the main points and conclusions from a discussion facilitated by OHE that focused on innovation in the pharmaceutical industry. Participants included…
The Impact of Health Technology Assessment on Drug Development
3 January 2009
Health technology assessment (HTA) has become a critical basis for pricing and reimbursement decision-making worldwide. In some countries, extensive requirements for data are set out in…
Medical Research: What’s It Worth?
1 November 2008
Understanding the nature, extent and processes involved in the return on investment in medical research has been largely neglected as an area of serious scientific study.…
Donor Investment Choices: Modeling the Value for Money of Investing in Product Development, Public Private Parnerships as Compared to Other Health Care and Non-Health Care Interventions
1 December 2006
Objective To model the cost-effectiveness for donors of investing in R&D projects into global diseases via public private partnerships for product development (PD PPPs). Methods We…
The Road to Sustainability in the UK and German Biotechnology Industries
1 August 2000
The UK and Germany are the European leaders in biotechnology. They have many more companies and employees in biotechnology, and much greater sums invested in biotechnology…
Surgical Research and Development in the NHS – Promotion, Management and Evaluation
1 July 2000
Based on papers delivered at the OHE Conference, London, 25 November 1997. Based on papers delivered at the OHE Conference, London, 25 November 1997. The UK…